Rapid test to identify Crimean-Congo hemorrhagic fever at the point of care
Official title: Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care
Run by Liverpool School of Tropical Medicine · NCT06624787 · Data updated 2026-11-12
A new rapid test is being tested to see if it can reliably detect Crimean-Congo hemorrhagic fever at the patient bedside in clinics in Turkey.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 492 (estimated) |
| Sponsor | Liverpool School of Tropical Medicine Academic / other |
| Locations | 6 sites (Erzurum and 5 other locations) |
| Status | Recruiting |
| Started | May 4, 2026 |
| Main results expected | September 2026 |
| Study ends | September 2027 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT06624787 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with suspected CCHF presenting at one of four designated sites in Turkey who require PCR confirmation and a venous blood draw.
✕Probably not a fit
Patients with non-CCHF illnesses or those who test negative might not benefit from the rapid test in terms of diagnostic accuracy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional diagnostic device study evaluates a novel lateral flow test for detecting Crimean-Congo hemorrhagic fever at the point of care. The study compares the rapid test results with the standard PCR test using samples from whole blood, serum, and capillary blood. It plans to enroll up to 492 adults suspected of infection across four endemic sites in Turkey. The goal is to achieve at least 90% sensitivity and 80% specificity, aligning with WHO requirements. Participants are adults 18+ who require RT-PCR confirmation and venous blood draws.
Why it matters
Potential benefit: If successful, the rapid test could permit quicker, on-site decisions for patient management and infection control.
How similar studies have gone: Prior studies in similar rapid diagnostic test contexts have shown variable performance; this study aims to validate effectiveness against PCR in a real-world setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Participants aged 18 years or older Suspected CCHF infection that requires a RT-PCR diagnosis and venous blood draw Willingness to comply with study procedures and consent to the study Presents at 1 of 4 listed sites Exclusion Criteria: * In the investigators opinion should not be enrolled onto study (e.g., medical prudence or capacity)
Where it's running
-
Atatürk University
Erzurum, Turkey (Türkiye) Recruiting -
Erzurum City Hospital
Erzurum, Turkey (Türkiye) Recruiting -
Kastamonu Üniversitesi
Kastamonu, Turkey (Türkiye) Recruiting -
Ondokuz Mayis University (OMU) Faculty of Medicine, Department of Clinical Microbiology and Infectious Diseases, Samsun
Samsun, Turkey (Türkiye) Recruiting -
Sivas Cumhuriyet University
Sivas, Turkey (Türkiye) Recruiting -
Tokat Gaziosmanpaşa University
Tokat Province, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Ravi Lad
- Email: ravi.lad@lstmed.ac.uk
- Phone: 151 705 3364
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adaptive Phase IIb Platform Trial to Test Therapies for Crimean-Congo Hemorrhagic Fever
A multi-arm, adaptive trial in adults with confirmed CCHF in Turkey and Iraq will test Favipiravir or Ribavirin against optimized standard care to see if these antivirals help clear the virus and improve outcomes.
-
Self-amplifying RNA vaccine for Crimean-Congo hemorrhagic fever in healthy adults
This will test whether different doses and a one- or two-dose schedule of the experimental HDT-321 vaccine are safe and trigger immune responses in healthy adults aged 18–64.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.